Protecting Clients Coast to Coast

If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD). STOCK DROP: On Monday, October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Preliminary data demonstrated patients’ baseline characteristics were similar across treatment arms, with the exception of percent predicted FVC, which was lower in the placebo-treated patients compared to the TTI-101-treated arms.

Did You Lose Money in WPP plc (NYSE: WPP) Stock? Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against WPP plc (“WPP” or the “Company”) for alleged violations of federal securities laws. The firm reminds investors that they have until December 8, 2025 to seek appointment as lead plaintiff in the class action filed against the Company. The complaint alleges that WPP and certain executives misled investors about the Company’s expected revenue for fiscal year 2025 and the strength of its media division, GroupM. While expressing confidence in new client wins and claiming to provide “cautious” guidance, WPP allegedly concealed that its media arm was losing market share and struggling to compete amid ongoing macroeconomic challenges. If you purchased WPP securities between February 27, 2025 and July 8, 2025, you may be eligible to recover your losses. Lead Plaintiff Deadline: December 8, 2025 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. This caused Plaintiff and other shareholders to purchase aTyr’s securities at artificially inflated prices. In the EFZO-FIT study, efzofitimod failed to show any change in mean daily oral corticosteroid (OCS) dose at week 48, with the OCS dose reducing by an average of 2.79mg for 5.0 mg/kg efzofitimod compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod versus 40.2% on placebo. After aTyr Pharma released the results, its stock dropped by 83.25%, from a September 12th market close of $6.03 to a September 15th market close of $1.01. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding ATyr’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the aTyr Pharma class action, go to www.faruqilaw.com/ATYR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Did You Lose Money in Marex Group plc (NASDAQ: MRX) Stock? Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marex Group plc (“Marex” or the “Company”) for alleged violations of federal securities laws. The firm reminds investors that they have until December 8, 2025 to seek appointment as lead plaintiff in the class action filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company sold over-the-counter financial instruments to itself; (2) Marex had inconsistencies in its financial statements between its subsidiaries and related parties, including as to intercompany receivables and loans; (3) as a result of the foregoing, Marex’s financial statements could not be relied upon; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you purchased Marex securities between May 16, 2024 and August 5, 2025, you may be eligible to recover your losses. Lead Plaintiff Deadline: December 8, 2025 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.